The superior clinical efficacy of PD-1 inhibitor pembrolizumab vs. chemotherapy is seen mainly in patients with high PD-L1-expressing tumours (TPS ≥ 50%) [16,17]. The gene discussed is PDCD1; the disease is neoplasm.